BOC Sciences is the industry leading expert in small molecular and protein engineering, also our rich experience could help us to provide comprehensive services for the conjugation and characterization of Protein-Drug Conjugation. With years of experience in the variety of organic synthesis and binding assays, we provide comprehensive expertise to support the development of protein-drug conjugate products for all phases of drug development from discovery to GMP manufacturing.
With the approval of antibody drug conjugation, more and more ADC entering clinical trials, targeted delivery of cytotoxic agents to cancer cells has been proved to be an effective way to treat cancer. This is true for hematological malignant tumors and solid tumors. So far, although efforts have been focused on using large full-length antibodies as payload delivery carriers, there is still considerable room for the use of smaller protein domains as targeting agents. These provide many potential benefits, including increased tumor permeability, adaptability to protein engineering and site-specific binding, and improved tolerance.
The use of special linkers makes protein drug conjugation unique in their in vivo therapeutic application by providing target tissue-specific release of drug. Several protein drug conjugates are currently in clinical trials to ensure that they have great market potential in the near future. In-depth understanding of this field will enable us to produce high-quality protein drug conjugates that will meet the therapeutic needs of drug delivery systems in the clinical environment.
- Novel site-specific conjugation technologies and robust methods
- Advanced equipment and technique
- Experienced scientific team
- Wide categories of biomolecule cross linking
- Data analysis, detailed report with results and discussion
- Cost-effective and high-quality products.